Literature DB >> 23307324

Enteric-coated mycophenolate sodium for progressive systemic sclerosis--a prospective open-label study with CT histography for monitoring of pulmonary fibrosis.

Joerg C Henes1, Marius Horger, Christopher Amberger, Marc Schmalzing, Gerhard Fierlbeck, Lothar Kanz, Ina Koetter.   

Abstract

The purpose of this study was to assess the impact of enteric-coated mycophenolate sodium (EC-MPS) on skin and pulmonary manifestations of patients with progressive systemic sclerosis (Ssc). A prospective, open-label single-centre trial with EC-MPS 2 × 720 mg/day over 12 months and a long-term follow-up of 50 months were conducted. Modified Rodnan skin score (mRSS) was used to assess the skin and pulmonary function tests to assess the pulmonary involvement. In order to quantify the extent of alveolitis/fibrosis via densitometry, the high attenuation value, median lung density and percentiles of lung tissue densities were obtained by high-resolution computed tomography. Eleven patients were included. Three patients had to stop medication before month 6 (2× side effects, 1× progression). For the remaining eight patients, the median mRSS was non-significantly reduced from 13.5 at baseline to 11 at month 12. According to the CT histography, median lung density and high attenuation values remained stable. However, the course of percentiles -200 to -300 and particularly -300 to -400 Hounsfield units slightly increased in seven of eight patients after 12 months, suggesting worsening of pulmonary involvement. Accordingly, median diffusing capacity for carbon monoxide showed a tendency to decline (75.1 % vs. 70.2) while forced vital capacity non-significantly improved (78.0 vs. 85.5 %) during the study. Four patients are still on EC-MPS without clinical signs of progression after 50 months follow-up. EC-MPS showed non-significant improvement of the skin. Pulmonary fibrosis remained stable with only a slight tendency towards progression which might be ascribed to the medication as well as the natural course of the disease. CT histography appears to be a sensitive method for the detection of progression of pulmonary fibrosis and therefore should be considered for further studies in Ssc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307324     DOI: 10.1007/s10067-012-2155-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life.

Authors:  Gianna Camiciottoli; Ilaria Orlandi; Maurizio Bartolucci; Eleonora Meoni; Francesca Nacci; Stefano Diciotti; Chiara Barcaroli; Maria Letizia Conforti; Massimo Pistolesi; Marco Matucci-Cerinic; Mario Mascalchi
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

2.  Whole-lung densitometry versus visual assessment of emphysema.

Authors:  Edoardo Cavigli; Gianna Camiciottoli; Stefano Diciotti; Ilaria Orlandi; Cheti Spinelli; Eleonora Meoni; Luca Grassi; Carmela Farfalla; Massimo Pistolesi; Fabio Falaschi; Mario Mascalchi
Journal:  Eur Radiol       Date:  2009-02-18       Impact factor: 5.315

3.  Effect of mycophenolate sodium in scleroderma-related interstitial lung disease.

Authors:  Carmen Pilar Simeón-Aznar; Vicent Fonollosa-Plá; Carles Tolosa-Vilella; Albert Selva-O'Callaghan; Roser Solans-Laqué; Miquel Vilardell-Tarrés
Journal:  Clin Rheumatol       Date:  2011-09-01       Impact factor: 2.980

4.  Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.

Authors:  S I Nihtyanova; G M Brough; C M Black; C P Denton
Journal:  Rheumatology (Oxford)       Date:  2006-08-09       Impact factor: 7.580

5.  A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.

Authors:  Fabian A Mendoza; Sarah J Nagle; Jason B Lee; Sergio A Jimenez
Journal:  J Rheumatol       Date:  2012-04-01       Impact factor: 4.666

6.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

7.  Quantitative CT assessment of chronic obstructive pulmonary disease.

Authors:  Shin Matsuoka; Tsuneo Yamashiro; George R Washko; Yasuyuki Kurihara; Yasuo Nakajima; Hiroto Hatabu
Journal:  Radiographics       Date:  2010-01       Impact factor: 5.333

8.  A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.

Authors:  Chris T Derk; Elizabeth Grace; Max Shenin; Manisha Naik; Steffan Schulz; Wen Xiong
Journal:  Rheumatology (Oxford)       Date:  2009-10-21       Impact factor: 7.580

9.  Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

Authors:  S N C Liossis; A Bounas; A P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2006-02-20       Impact factor: 7.580

10.  A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis.

Authors:  M Vanthuyne; D Blockmans; R Westhovens; F Roufosse; E Cogan; E Coche; A Nzeusseu Toukap; G Depresseux; F A Houssiau
Journal:  Clin Exp Rheumatol       Date:  2007 Mar-Apr       Impact factor: 4.473

View more
  1 in total

Review 1.  Management of Systemic-Sclerosis-Associated Interstitial Lung Disease.

Authors:  Katherine Culp Silver; Richard M Silver
Journal:  Rheum Dis Clin North Am       Date:  2015-05-23       Impact factor: 2.670

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.